Roquefort Investments PLC Exercise of Warrants & Total Voting Rights (8158X)
07 Mayo 2021 - 01:00AM
UK Regulatory
TIDMROQ
RNS Number : 8158X
Roquefort Investments PLC
07 May 2021
7 May 2021
roquefort investments PLC
("Roquefort Investments" or the "Company")
Exercise of Warrants & Total Voting Rights
Roquefort Investments plc, an investment company established to
acquire businesses focused on early stage opportunities in the
medical biotechnology sector, announces that it has received a
notice to exercise warrants over a total of 1,500,000 Ordinary
Shares (the "Warrant Shares"), for which funds of GBP15,000 have
been received by the Company.
Application has been made for the admission of the Warrant
Shares to trading on the Main Market of the London Stock Exchange,
with such admission expected to become effective at 8.00 a.m. on
12th May 2021 ("Admission").
Following Admission, the total issued share capital of the
Company will consist of 33,900,000 ordinary shares of one penny
each. This number may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
Enquiries:
Roquefort Investments plc
+44 (0)20 3290
Stephen West (Chairman) 9339
Optiva Securities Limited (Broker)
+44 (0)20 3411
Christian Dennis 1881
For further information, please visit www.roquefortinvest.com and @roquefortinvest on Twitter.
About Roquefort Investments
Roquefort Investments was formed as an investment company to
acquire businesses focused on early-stage opportunities in the
medical biotechnology sector with the aim of generating optimal
returns for both the target businesses and our shareholders. It is
envisaged that such acquisition or acquisitions will trigger a
reverse takeover in accordance with the listing rules.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRDKABDBBKDKPK
(END) Dow Jones Newswires
May 07, 2021 02:00 ET (06:00 GMT)
Roquefort Therapeutics (LSE:ROQ)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Roquefort Therapeutics (LSE:ROQ)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024